Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program - Seite 4

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [e-mail]

# # #

Novartis Media Relations
E-mail: [e-mail]

Anja von Treskow Novartis External Communications [phone] (mobile) [e-mail]   Eric Althoff Novartis US External Communications [phone] [e-mail]

Farah Bulsara Speer SVP, Corporate Communications, Novartis Gene Therapies [phone] (mobile) [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Sloan Simpson	[phone]
Thomas Hungerbuehler         Isabella Zinck	[phone] [phone]